Alzamend Neuro, Inc. - Common Stock (NQ:ALZN)

1.458 +0.088 (+6.43%)

Delayed Quote Updated: 1:11 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Alzamend Neuro, Inc. - Common Stock

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Ault Alliance Announces Alzamend Neuro Has Initiated Its Phase I/IIA Trial for Its Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type

April 04, 2023

From Ault Alliance, Inc.

Via Business Wire

EXCLUSIVE: Alzamend Neuro Starts Phase 1/2A Trial For Its Alzheimer's Immunotherapy Vaccine ↗

April 03, 2023

Alzamend Neuro Inc (NASDAQ: ALZN) has initiated a Phase 1/2A trial for its immunotherapy vaccine (ALZN002) to treat mild to moderate dementia of Alzheimer’s type.

Via Benzinga

EXCLUSIVE: Alzamend Neuro Completes Clinical Portion Of Mid-Stage Alzheimer's Trial ↗

March 22, 2023

Alzamend Neuro Inc (NASDAQ: ALZN) announced it had completed the clinical portion of its Phase 2A multiple ascending dose (MAD) study of AL001 in subjects with dementia related to Alzheimer’s.

Via Benzinga

Alzamend Neuro Adds Healthy Subjects to Ongoing Mid-Stage Alzheimer's Trial ↗

October 05, 2022

Via Benzinga

Alzamend Neuro Seeks FDA Nod For Dementia Immunotherapy Study ↗

September 29, 2022

Via Benzinga

KILL Alzamend Neuro Receives FDA “Study May Proceed” Letter for Phase I/IIA Trial Under Its Investigational New Drug Application for an Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type

April 03, 2023

Via Business Wire

Why Hertz Global Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket ↗

March 06, 2023

Gainers Secoo Holding Limited (NASDAQ: SECO) rose 44% to $1.44 in pre-market trading after dipping over 31% on Friday.

Via Benzinga

Alzamend Neuro Announces the Initiation of a Phase I/IIA Trial for Its Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type

April 03, 2023

From Alzamend Neuro, Inc.

Via Business Wire

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

February 14, 2023

Via Benzinga

Alzamend Neuro Announces Completion of Clinical Portion of Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s

March 22, 2023

From Alzamend Neuro, Inc.

Via Business Wire

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

January 10, 2023

Via Benzinga

Alzamend Neuro Reports Third Fiscal Quarter Financial Results and Provides a Business Update

March 16, 2023

From Alzamend Neuro, Inc.

Via Business Wire

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

December 28, 2022

Via Benzinga

EXCLUSIVE: Alzamend Neuro Partners With Stem Cell Institute For Immunotherapy Vaccine Trial For Dementia ↗

December 28, 2022

Alzamend Neuro Inc (NASDAQ: ALZN) has partnered with the Miller School of Medicine, Interdisciplinary Stem Cell Institute at the University of Miami for its Phase 1/2A trial of ALZN002.

Via Benzinga

Alzamend Neuro to Present at Sequire Biotechnology Conference

January 26, 2023

From Alzamend Neuro, Inc.

Via Business Wire

SEC Goes After 'MrZackMorris, 'Stock Sniper' For Alleged Fraud ↗

December 14, 2022

Eight people connected to Atlas Trading, a Discord-based community, have been named in a complaint filed by the Securities and Exchange Commission (SEC). Co-founders of the forum, podcasters, and...

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗

December 02, 2022

We're starting off the day with an overview of the biggest pre-market stock movers traders need to know about for Friday morning!

Via InvestorPlace

Alzamend Neuro Partners With Biorasi to Conduct a First-in-Human, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase I/IIA Clinical Trial

January 04, 2023

From Alzamend Neuro, Inc.

Via Business Wire

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

November 29, 2022

Via Benzinga

Alzamend Neuro Partners With the Miller School of Medicine, Interdisciplinary Stem Cell Institute at the University of Miami for ALZN002 Phase I/IIA Immunotherapy Vaccine Clinical Trial to Treat Mild to Moderate Dementia of the Alzheimer’s Type

December 28, 2022

From Alzamend Neuro, Inc.

Via Business Wire

In a New Audio Interview, Toni Loudenbeck of Traders News Source Interviews Stephan Jackman, CEO Alzamend Neuro, Inc.

November 22, 2022

Via ACCESSWIRE

Stocks That Hit 52-Week Lows On Friday ↗

December 23, 2022

OnFriday, 143 stocks hit new 52-week lows.

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

November 16, 2022

Via Benzinga

Alzamend Neuro CEO Stephan Jackman to Appear on Fox Business Network to Discuss Therapeutic Pipeline

November 15, 2022

From Alzamend Neuro, Inc.

Via Business Wire

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗

November 02, 2022

Good morning, trader! It's time to take a look at all of the latest news behind the biggest pre-market stock movers on Thursday!

Via InvestorPlace

5.6 Million Bet On This Penny Stock? Check Out These 3 Penny Stocks Insiders Are Buying ↗

November 02, 2022

The Nasdaq Composite closed lower by around 100 points on Tuesday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or...

Via Benzinga

WaveDancer And 1 Other Stock Under $2 Insiders Are Aggressively Buying ↗

October 10, 2022

The Dow Jones dropped by more than 600 points on Friday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern...

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗

October 05, 2022

It's time for another overview of the biggest pre-market stock movers for Wednesday as we cover the news behind share movement this morning!

Via InvestorPlace

Alzamend Neuro Receives FDA “Study May Proceed” Letter for Phase I/IIA Trial Under Its Investigational New Drug Application for an Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type

October 31, 2022

From Alzamend Neuro, Inc.

Via Business Wire

Alzamend Neuro Announces Addition of Healthy Subjects to Ongoing Phase IIA Clinical Trial for AL001 in Alzheimer’s Subjects

October 05, 2022

From Alzamend Neuro, Inc.

Via Business Wire

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.